Relay Therapeutics, Inc. (RLAY) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.91
↑+93% vs avg
5yr avg: 2.03
30Y Low0.8·High4.9
ROE
↑
-41.1%
-2% vs avg
5yr avg: -40.1%
30Y Low-44%·High-18%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RLAY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Relay Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.4B | $1.5B | $589M | $1.3B | $1.7B | $2.9B | $3.7B | — | — |
| Enterprise Value | $2.4B | $1.4B | $513M | $1.3B | $736M | $2.7B | $3.3B | — | — |
| P/E Ratio → | -8.02 | — | — | — | — | — | — | — | — |
| P/S Ratio | 159.20 | 94.54 | 58.82 | 52.83 | 1214.17 | 964.56 | 45.35 | — | — |
| P/B Ratio | 3.91 | 2.56 | 0.76 | 1.79 | 1.76 | 3.25 | 4.91 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RLAY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 91.18 | 51.25 | 49.30 | 532.65 | 879.64 | 40.23 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
RLAY Profitability
Margins and return-on-capital ratios measuring operating efficiency
Relay Therapeutics, Inc. earns an operating margin of -1971.6%. Operating margins have compressed from -1460.1% to -1971.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -41.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.8% | 76.8% | 100.0% | 100.0% | 100.0% | 100.0% | 95.7% | — | — |
| Operating Margin | -1971.6% | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% | -67.5% | — | — |
| Net Profit Margin | -1800.6% | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.1% | -41.1% | -44.2% | -40.2% | -31.4% | -43.8% | -18.0% | — | — |
| ROA | -37.0% | -37.0% | -39.4% | -35.2% | -27.6% | -40.2% | -8.8% | -16.2% | -11.4% |
| ROIC | -37.3% | -37.3% | -41.0% | -83.4% | -69.1% | -55.8% | -58.7% | — | — |
| ROCE | -42.7% | -42.7% | -45.6% | -40.3% | -29.6% | -41.2% | -9.6% | -20.9% | -11.8% |
RLAY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $84M exceeds total debt of $32M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.06 | 0.07 | 0.06 | 0.03 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.10 | -0.12 | -0.99 | -0.29 | -0.55 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($84M) exceeds total debt ($32M)
RLAY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Relay Therapeutics, Inc.'s current ratio of 22.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 25.44x to 22.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 22.61 | 22.61 | 15.95 | 25.44 | 16.00 | 40.14 | 56.49 | 30.08 | 61.78 |
| Quick Ratio | 22.61 | 22.61 | 15.95 | 25.44 | 15.81 | 40.14 | 56.49 | 30.08 | 61.78 |
| Cash Ratio | 21.68 | 21.68 | 15.40 | 24.78 | 15.68 | 39.39 | 49.74 | 29.69 | 61.40 |
| Asset Turnover | — | 0.02 | 0.01 | 0.03 | 0.00 | 0.00 | 0.10 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 1379.39 | 595.28 | 365.00 | — | — |
RLAY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Relay Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $172M | $143M | $123M | $112M | $95M | $90M | $4M | $2M |
Peer Comparison
Compare RLAY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RLAYYou | $2B | -8.0 | — | — | 76.8% | -1971.6% | -41.1% | -37.3% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 VKTX | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
 ERAS | $3B | -15.8 | — | — | — | — | -43.7% | -39.2% | — |
 MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 AUPH | $2B | 7.8 | 20.4 | 15.9 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 NUVL | $7B | -26.5 | — | — | — | — | -29.5% | -32.6% | — |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See RLAY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLAY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RLAY vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonRLAY — Frequently Asked Questions
Quick answers to the most common questions about buying RLAY stock.
What is Relay Therapeutics, Inc.'s P/E ratio?
Relay Therapeutics, Inc.'s current P/E ratio is -8.0x. This places it at the 50th percentile of its historical range.
What is Relay Therapeutics, Inc.'s ROE?
Relay Therapeutics, Inc.'s return on equity (ROE) is -41.1%. The historical average is -36.4%.
Is RLAY stock overvalued?
Based on historical data, Relay Therapeutics, Inc. is trading at a P/E of -8.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Relay Therapeutics, Inc.'s profit margins?
Relay Therapeutics, Inc. has 76.8% gross margin and -1971.6% operating margin.